glp-1 lawsuit 2025 Receptor Agonists: Drug Litigation Overview and Trends GLP-1 Drugs: 2025 Pulse Survey

The absence of a boxed warning on cagrilintide reflects the absence of an approved label not a demonstration that it is safer

Semaglutide carries a warning about potential worsening of diabetic retinopathy, particularly in patients with pre-existing retinopathy and rapid improvement in glucose control

DOI: 10.1038/s41586-026-10330-z) im Bereich der Rezeptoren fr das Glucagon-like Peptide-1 (GLP-1) und des glukoseabhngigen insulinotropen Peptids (GIP), ber die die beiden Medikamente ihre Wirkung erzielen

Psoriasis in Tigray, Ethiopia: focusing on available treatments

Musavvir says its not just a hormonal or reproductive issue